These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

458 related articles for article (PubMed ID: 26820289)

  • 1. Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
    Brahmi M; Vinceneux A; Cassier PA
    Curr Treat Options Oncol; 2016 Feb; 17(2):10. PubMed ID: 26820289
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of imatinib mesylate for the treatment of locally advanced and/or metastatic tenosynovial giant cell tumor/pigmented villonodular synovitis.
    Cassier PA; Gelderblom H; Stacchiotti S; Thomas D; Maki RG; Kroep JR; van der Graaf WT; Italiano A; Seddon B; Dômont J; Bompas E; Wagner AJ; Blay JY
    Cancer; 2012 Mar; 118(6):1649-55. PubMed ID: 21823110
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of tenosynovial giant cell tumor and pigmented villonodular synovitis.
    Ravi V; Wang WL; Lewis VO
    Curr Opin Oncol; 2011 Jul; 23(4):361-6. PubMed ID: 21577109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
    Cassier PA; Italiano A; Gomez-Roca CA; Le Tourneau C; Toulmonde M; Cannarile MA; Ries C; Brillouet A; Müller C; Jegg AM; Bröske AM; Dembowski M; Bray-French K; Freilinger C; Meneses-Lorente G; Baehner M; Harding R; Ratnayake J; Abiraj K; Gass N; Noh K; Christen RD; Ukarma L; Bompas E; Delord JP; Blay JY; Rüttinger D
    Lancet Oncol; 2015 Aug; 16(8):949-56. PubMed ID: 26179200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides.
    Cupp JS; Miller MA; Montgomery KD; Nielsen TO; O'Connell JX; Huntsman D; van de Rijn M; Gilks CB; West RB
    Am J Surg Pathol; 2007 Jun; 31(6):970-6. PubMed ID: 17527089
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment updates on tenosynovial giant cell tumor.
    Palmerini E; Staals EL
    Curr Opin Oncol; 2022 Jul; 34(4):322-327. PubMed ID: 35837703
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pigmented villonodular synovitis therapy with MSCF-1 inhibitors.
    Temple HT
    Curr Opin Oncol; 2012 Jul; 24(4):404-8. PubMed ID: 22572726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nilotinib in locally advanced pigmented villonodular synovitis: a multicentre, open-label, single-arm, phase 2 trial.
    Gelderblom H; Cropet C; Chevreau C; Boyle R; Tattersall M; Stacchiotti S; Italiano A; Piperno-Neumann S; Le Cesne A; Ferraresi V; Penel N; Duffaud F; Cassier P; Toulmonde M; Casali P; Taieb S; Guillemaut S; Metzger S; Pérol D; Blay JY
    Lancet Oncol; 2018 May; 19(5):639-648. PubMed ID: 29571946
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extensile Anterior and Posterior Knee Exposure for Complete Synovectomy of Diffuse Tenosynovial Giant Cell Tumor (Pigmented Villonodular Synovitis).
    Lingamfelter M; Novaczyk ZB; Cheng EY
    JBJS Essent Surg Tech; 2022; 12(2):. PubMed ID: 36741035
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse-type tenosynovial giant cell tumour: Current treatment concepts and future perspectives.
    Staals EL; Ferrari S; Donati DM; Palmerini E
    Eur J Cancer; 2016 Aug; 63():34-40. PubMed ID: 27267143
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term follow-up of nilotinib in patients with advanced tenosynovial giant cell tumours: Long-term follow-up of nilotinib in TGCT.
    Spierenburg G; Grimison P; Chevreau C; Stacchiotti S; Piperno-Neumann S; Le Cesne A; Ferraresi V; Italiano A; Duffaud F; Penel N; Metzger S; Chabaud S; van der Heijden L; Pérol D; van de Sande MAJ; Blay JY; Gelderblom H
    Eur J Cancer; 2022 Sep; 173():219-228. PubMed ID: 35932628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT).
    Blay JY; El Sayadi H; Thiesse P; Garret J; Ray-Coquard I
    Ann Oncol; 2008 Apr; 19(4):821-2. PubMed ID: 18296418
    [No Abstract]   [Full Text] [Related]  

  • 13. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villonodular synovitis.
    Fiocco U; Sfriso P; Lunardi F; Pagnin E; Oliviero F; Scagliori E; Cozzi L; Vezzù M; Molena B; Scanu A; Panziera C; Nardacchione R; Rubaltelli L; Dayer JM; Calabrese F; Punzi L
    Autoimmun Rev; 2010 Sep; 9(11):780-4. PubMed ID: 20620241
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of Pigmented Villonodular Synovitis (PVNS): an Orthopedic Surgeon's Perspective.
    Bernthal NM; Ishmael CR; Burke ZDC
    Curr Oncol Rep; 2020 Jun; 22(6):63. PubMed ID: 32494892
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tenosynovial giant cell tumor: case report of a patient effectively treated with pexidartinib (PLX3397) and review of the literature.
    Giustini N; Bernthal NM; Bukata SV; Singh AS
    Clin Sarcoma Res; 2018; 8():14. PubMed ID: 30002809
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells.
    West RB; Rubin BP; Miller MA; Subramanian S; Kaygusuz G; Montgomery K; Zhu S; Marinelli RJ; De Luca A; Downs-Kelly E; Goldblum JR; Corless CL; Brown PO; Gilks CB; Nielsen TO; Huntsman D; van de Rijn M
    Proc Natl Acad Sci U S A; 2006 Jan; 103(3):690-5. PubMed ID: 16407111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structure-Guided Blockade of CSF1R Kinase in Tenosynovial Giant-Cell Tumor.
    Tap WD; Wainberg ZA; Anthony SP; Ibrahim PN; Zhang C; Healey JH; Chmielowski B; Staddon AP; Cohn AL; Shapiro GI; Keedy VL; Singh AS; Puzanov I; Kwak EL; Wagner AJ; Von Hoff DD; Weiss GJ; Ramanathan RK; Zhang J; Habets G; Zhang Y; Burton EA; Visor G; Sanftner L; Severson P; Nguyen H; Kim MJ; Marimuthu A; Tsang G; Shellooe R; Gee C; West BL; Hirth P; Nolop K; van de Rijn M; Hsu HH; Peterfy C; Lin PS; Tong-Starksen S; Bollag G
    N Engl J Med; 2015 Jul; 373(5):428-37. PubMed ID: 26222558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pexidartinib, a Novel Small Molecule CSF-1R Inhibitor in Use for Tenosynovial Giant Cell Tumor: A Systematic Review of Pre-Clinical and Clinical Development.
    Benner B; Good L; Quiroga D; Schultz TE; Kassem M; Carson WE; Cherian MA; Sardesai S; Wesolowski R
    Drug Des Devel Ther; 2020; 14():1693-1704. PubMed ID: 32440095
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CSF1R-positive tenosynovial giant cell tumor cell lines and their pexidartinib (PLX3397) and sotuletinib (BLZ945)-induced apoptosis.
    Thongchot S; Duangkaew S; Yotchai W; Maungsomboon S; Phimolsarnti R; Asavamongkolkul A; Thuwajit P; Thuwajit C; Chandhanayingyong C
    Hum Cell; 2023 Jan; 36(1):456-467. PubMed ID: 36456782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: initial experience of molecularly targeted therapy.
    Nakayama R; Jagannathan JP; Ramaiya N; Ferrone ML; Raut CP; Ready JE; Hornick JL; Wagner AJ
    BMC Cancer; 2018 Dec; 18(1):1296. PubMed ID: 30594158
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.